Viropro's protein production expertise combined with Invitrogen PD Direct™'s media and cell line development expertise will yield new solutions for pharmaceutical and biotech companies.
This collaboration would represent recurring revenues and royalties for Viropro following integration of the technology with Invitrogen PD Direct™'s customized media platforms.
Additionally, Viropro has an opportunity to out-license the technology and sign intellectual property (IP) agreements with other major biotech companies interested in integrating novel IP into their research and manufacturing processes.
“The fact that an industry leader like Invitrogen has shown a concrete interest in our technology is a clear sign of Viropro's ability to choose innovative and cutting edge intellectual property for the realization of our business model,” said Viropro CEO, Jean-Marie Dupuy.
Jeff Greenberg, VP of BioProduction of Invitrogen stated that, “We are enthusiastic about testing this new technology and hope to establish a long-term relationship with Viropro.”